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Biotechnological drugs are a wide group of therapeutic
agents obtained by means of genetic engineering methodolo-
gies. They act through the inhibition of specific cytokines/
cells involved in the cascade of different pathological pro-
cesses, leading to the modification of host immune response.
Themain targets of these drugs are TNF-𝛼, IL-6, IL-1, and
B and T cells. In the latest years, according to the improved
knowledge in the pathogenesis of several diseases, the use of
these drugs is steadily increasing, and new agents have been
marketed or are under development.
Autoimmune rheumatic diseases are the prototypical
example of pathological conditions that may benefit from
these therapies. Biotechnological drugs deeply improved
patients’ prognosis and quality of life in several rheumatic
conditions, as, for example, rheumatoid arthritis (RA).
Despite the large number of papers published and the large
clinical experience obtained for some of these drugs, there
are still many questions that should be clarified. This special
issue is addressed to the analysis of some peculiar aspects of
these drugs, in both clinic and research context.
F. Atzeni et al. evaluated in a real life study the effects
of anti-TNF-𝛼 drugs on RA related disability, suggesting that
benefits from these therapies may be relevant also in patients
with long-standing diseases. Interestingly, results showed
that the improvement in disability was marked during the
first year of anti-TNF therapy, with a subsequent slower but
significant recovery over the subsequent four years.
The article by L. Cavagna and W. J. Taylor is focused on
gout: this disease is the typical example of how, in few years,
technologic advances improved therapeutic approach. New
and old biologics on pipeline are extensively reviewed, in
order to help clinicians in their daily activity.
E. G. Favalli et al. managed an interesting review
addressed to RA therapeutic approach: they demonstrate
that, with respect to treatments available, up to now only
a limited number of head-to-head randomized controlled
trials are available, with subsequent limitations in the optimal
use of different drugs available in daily practice. However,
the authors provided some preliminary but encouraging
suggestions on how to deal with the complexity of the
available therapeutic armamentarium.
M. Schulz et al. assessed the differences in TNF-𝛼 reg-
ulation in patients with ankylosing spondylitis (AS) and
RA being treated with infliximab and etanercept. Results
suggested that drug metabolism between these diseases is
different and they are a further input for the pathogenetic
studies in both conditions.
The paper of F. Genre et al. deeply analysed the role of
adipokines in the assessment of cardiovascular risk of AS,
particularly in anti-TNF-𝛼 treated patients. By considering
the impact of cardiovascular mortality in the setting, authors’
suggestions are an important impulse for further studies on
these interesting molecules.
Finally, Y. Hu et al. first analysed the role of a peculiar
neuronal nicotinic acetylcholine receptor, named 𝛼7nAChR,
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and of its partial agonist GTS-21 in the experimental model
of collagen induced arthritis (CIA), identifying another
interesting and potential target of treatment in RA.
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